Back to Search
Start Over
Vertex: EMA Validates Marketing Authorization Application Extension for KAFTRIO in Combination with Ivacaftor
- Source :
- Wireless News. December 8, 2023
- Publication Year :
- 2023
-
Abstract
- Vertex Pharmaceuticals reported that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor. The company said [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Wireless News
- Publication Type :
- News
- Accession number :
- edsgcl.775736291